Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma

Catalysis SL

Status and phase

Completed

Phase 2

Conditions

Advanced Cancer

Pancreatic Diseases

Endocrine Gland Neoplasms

Digestive System Diseases

Adenocarcinoma of the Pancreas

Digestive System Neoplasms

Endocrine System Diseases

Pancreatic Neoplasms

Pancreatic Cancer

Treatments

Dietary Supplement: Ocoxin-Viusid®

Study type

Interventional

Funder types

Industry

Identifiers

NCT03717298

OOS-CANCER-6

Details and patient eligibility

About

The investigators hypothesized that with the administration of the nutritional supplement Ocoxin-Viusid® is expected to improve the quality of life and enhance tolerance to chemotherapy in at least 70% of patients diagnosed with advanced pancreatic adenocarcinoma, treated at the "Hermanos Ameijeiras" Surgical Clinical Hospital. Phase II clinical trial, open, multicenter, nonrandomized.

Full description

To assess the effect of Ocoxin-Viusid® on the quality of life of patients with advanced pancreatic adenocarcinoma.

To evaluate the effect of Ocoxin-Viusid® on the quality of life of patients. To evaluate the influence of Ocoxin-Viusid® on tolerance to onco-specific therapy.

Identify the changes that occur in the nutritional status of patients receiving the supplement.

To evaluate the toxicity of Ocoxin-Viusid® in combination with chemotherapy in patients with advanced pancreatic adenocarcinoma.

Enrollment

30 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients of any sex, resident in Cuba, with an age greater than or equal to 18 years.
Patients that meet the diagnostic criteria.
Patients with general health according to Karnofsky ≥70 %.
Life expectancy greater than or equal to 3 months.
Patients eligible to receive chemotherapy.
Patients who have signed the informed consent.
Patients who have laboratory values in parameters that do not contraindicate the administration of chemotherapy:
Hemoglobin ≥ 90 g / l.
Total Leukocyte Count ≥ 3.0 x 109 / L.
Absolute Neutrophil Count ≥1.5 x 109 / L.
Platelet count ≥100 x 109 / L.
Total bilirubin values ≤ 1.5 times the upper limit of the normal range established in the institution.
TGO and TGP values ≤2.5 times the upper limit of the normal interval established in the institution.
Creatinine values within the normal limits of the institution.

Exclusion criteria

Pregnant or lactating patients.
Patients with known hypersensitivity to any of the active ingredients of the chemotherapy used
Patients who are receiving another product under investigation.
Patients with decompensated intercurrent diseases, including: hypertension, diabetes mellitus, ischemic heart disease, active infections, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, liver damage or any other special condition that at the discretion of the doctor puts their health at risk and his life during the study or his participation in the trial.
Patients with brain metastases.
Patients with mental disorders that may limit adherence to the requirements of the clinical trial and may hinder the collection of information, treatment or follow-up.

It is planned to include a total of 30 patients in the study, taking into account 10% of losses.